<DOC>
	<DOC>NCT00653445</DOC>
	<brief_summary>The purpose of this study is to compare 6 weeks of treatment with rosuvastatin alone compared with 6 weeks of treatment of rosuvastatin combined with ezetimibe in achieving low density lipoprotein level goals.</brief_summary>
	<brief_title>Compare the Safety &amp; Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>A history of CHD or clinical evidence of atherosclerosis or multiple risk factors that confer a high risk as defined in the protocol. Fasting LDLC concentrations at Visit 1 as defined in the protocol. Discontinuation of all lipid lowering therapy at Visit 1. History of statin induced serious side effects, or serious hypersensitivity reaction to other statins. Subjects considered to be unstable by the investigator after the following events: a myocardial infarction (heart attack), unstable angina, myocardial revascularisation or another revascularisation procedure or a transient ischaemic attack (TIA) or stroke. Severe congestive cardiac failure (as defined by the protocol Appendix I). Subjects awaiting a planned myocardial revascularisation prior to starting the study (i.e. planned prior to visit 1)..</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Low density lipoproteins</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Coronary Heart Disease</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Crestor</keyword>
	<keyword>Ezetimibe</keyword>
</DOC>